Abstract
Low molecular weight heparins (LMWH) and anti-Xa direct oral anti-coagulants (DOACs) are recommended for the long-term treatment of cancer-associated thrombosis (CAT) based on well-documented randomised controlled trials. Anti-Xa DOACs are viewed as a first choice for the treatment of patients with CAT. A large number of drug–drug interactions have been reported between DOACs and chemotherapy drugs, modifying circulating levels of DOAC leading to fears of increased bleeding risks or thrombotic recurrence. Progresses in anti-neoplastic therapies have improved the prognosis and the survival, thus increasing the prevalence of frail patients with cancer. However, since frailties tend to be excluded from large trials due to multiple co-morbidities, current guidelines are not fully applicable to this population. The management of these frail patients with CAT is particularly complex and requires a risk assessment on a case-by-case basis with specific focus on cancer, patient-related risk factors and drug–drug interactions. In this brief review we have identified age, co-morbidities and co-medications as key factors of frailty that require careful attention and we have developed a therapeutic decision algorithm to help clinicians optimising the use of anti-coagulants in patients with cancer with CAT, especially in case of anti-Xa DOACs concomitant medications. With the evaluation of the bleeding risk according to the type of cancer, and anticipating drug–drug interactions intensity, taking into account patient frailties allows the optimisation of the anti-coagulant choice. A systematic collaboration between oncologists, vascular pathology specialists and pharmacists is warranted to ensure an optimal patient management. Clinical studies are needed to determine the real impact of these interactions.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Frail patients with cancer with cancer-associated thrombosis (CAT) are at higher risk of complications due to drug–drug interactions between direct oral anti-coagulants and anti-neoplastic drugs. Most of them are preventable, being associated to clinical situations and metabolic pathways. |
A therapeutic decision algorithm taking in account patient frailties is proposed for the choice of an anti-coagulant for the treatment of patients with cancer-associated thrombosis. |
A systematic collaboration between oncologists, vascular pathology specialists, pharmacologists and pharmacists is warranted to ensure an optimal patient management. |
1 Introduction
Recent major therapeutic advances have led to an increase in the overall survival of patients with cancer. Population risk factors (e.g. elderly, smoking in women) are associated with an increase in the incidence of cancers. Also, anti-cancer drugs are used for longer treatment periods, resulting in a sharp increase in the prevalence of patients with cancer receiving anti-neoplastic treatments [1, 2].
The thrombotic risk in patients treated for cancer is increased seven-fold compared with the cancer-free population [3], while the bleeding risk is multiplied by two to three times [4]. Venous thromboembolic (VTE) disease represents the second leading cause of death after neoplastic progression [5]. The individual risk of VTE recurrence or bleeding must be assessed specifically for each patient to support the choice of anti-coagulation.
The 2019 American Society of Clinical Oncology (ASCO) [6] and 2022 International Initiative on Thrombosis and Cancer (ITAC) [7] guidelines recommend anti-Xa direct oral anti-coagulants (DOACs), including rivaroxaban, apixaban and edoxaban, for the treatment of cancer-associated thrombosis (CAT) in patients treated with systemic anti-cancer therapy, without bleeding risk and in the absence of drug–drug interactions with the anti-cancer treatment, or other concomitant therapy. DOACs are factor Xa inhibitors and/or factor IIa inhibitors. Caution is recommended in patients with gastrointestinal cancers, especially in unresected intra-luminal tumour and in genitourinary tumours, due to the high risk of bleeding observed with anti-Xa DOACs. Anti-Xa DOACs are not indicated in several haematologic cancers as thrombocytopaenia is frequently associated with the disease and/or the anti-neoplastic treatment. The recommended duration for the anti-coagulant treatment is at least 6 months and then extended as long as the cancer is active. A cancer is considered active when one of the three following conditions is present: the cancer has not received potentially curative treatment, the evidence shows that treatment has not been curative (recurrence, progression), or the cancer treatment is ongoing.
Like other drugs eliminated through metabolic pathways, the use of anti-Xa DOACs require the detection of the risk of drug–drug interactions (DDIs) with concomitant medications. Anti-Xa DOACs approved for the treatment of CAT are eliminated by the cytochrome P 450 (CYP) 3A4/5 enzymes and by P-glycoprotein (P-gp), leading to an increased bleeding or thrombotic risk when associated to strong CYP 3A4/5 and/or P-gp inhibitors or inductors, respectively.
Patients at high risk of VTE recurrence and high risk of bleeding are particularly vulnerable to DDIs.
Co-morbidities are common, and their incidence increases during the course of the disease. Patient frailty can lead to reduced DOAC elimination, resulting in an increased risk of bleeding or an increased likelihood of clinically relevant DDIs. There is no validated predictive score for bleeding in patients treated for cancer, whereas frailties are known to increase the bleeding risk in patients with atrial fibrillation treated with anti-coagulants [8]. In the absence of validated predictive bleeding scores, the RIETE bleeding risk score predicting fatal bleeding may be useful in patients with CAT, as cancer is known as a factor of frailty [9, 10]. Patient frailty increases with the number of co-morbidities and the severity of clinical consequences in the case of DDIs. The co-morbidities which seem to be the most relevant to be taken into account include renal insufficiency, hepatic function disorders, undernutrition and obesity, since they modify the pharmacokinetics of anti-coagulants. Caution is required in frail patient in oncology and geriatrics. In addition, mucosal diseases and thrombocytopaenia may increase the risk of bleeding complications. In this context, taking frailty into account, an age-related condition of increased vulnerability to acute endogenous or exogenous stressors is key to optimise treatment strategy. The gold standard to assess frailty in older adults with cancer is geriatric screening followed by geriatric assessment (GA) across essential GA-domains (social status, physical function, nutrition, cognition, emotion, co-morbidity, polypharmacy). GA enables tailoring of both oncological therapy and non-oncological interventions to the patient’s vulnerabilities.
This review aims to consider the impact of key factors that contribute to patient’s frailty on the anti-coagulation strategy and to discuss a decision-making algorithm for the management of patients with CAT and help with the choice between DOAC and LMWH.
2 Frailties and Risk Factors Influencing VTE Management
Main factors that contribute to patient’s frailty include the type of cancer and individual patient characteristics, such as creatinine clearance, liver function tests, age, BMI platelets rate and DDIs with anti-neoplastic treatments, and concomitant medications [11].
2.1 Cancer-Related Risk Factors
When prescribing anti-Xa DOACs, an additional risk of bleeding must be considered for unresected endoluminal digestive urothelial cancers and mucosal gynaecological cancers. Moreover, acute leukaemia, frequently associated with long-lasting thrombocytopaenia, exposes the patient to an important bleeding risk. Also, an increased thrombotic recurrence risk was reported in patients with multiple myeloma, pancreatic cancers, or lung cancer included in the RIETE registry [12]. However, no CAT recurrence risk score has been fully validated to date, including the Ottawa score.
2.2 Patient-Related Risk Factors
Metabolism is influenced by patient-specific factors, such as comorbidities and genetics, therapeutic-specific factors, including drug characteristics and interactions, and disease-specific factors, such as organ dysfunction [13].
2.2.1 Chronic Kidney Disease
The prevalence of chronic kidney disease (CKD) in patients with cancer is common and may depend on the type of cancer, being higher in patients with renal cancer (50%), urinary tract cancer (1 of 3 patients) and pancreatic cancer (1 of 5 patients) [14, 15]. The prevalence of CKD is lower in patients with colon cancers (5.3%) and brain tumours (2.5%) [16].
Renal elimination varies between anti-Xa DOACs: 50% for edoxaban, 36% for rivaroxaban and 27% for apixaban [17, 18]. Variations in anti-Xa DOACs plasma concentration in case of renal impairment are summarised in Table 1.
Bleeding is more common in patients with higher anti-Xa DOACs peak levels [19]. In patients with intermediate clearance between 30 and 49 ml/min, anti-Xa DOACs are well tolerated without dose adjustment. Full doses of anti-Xa DOACs are contraindicated by European recommendations when creatinine clearance is below 30 ml/min for rivaroxaban and edoxaban, or 25 ml/min for apixaban. On the contrary, the US Food and Drug Administration (FDA) allows apixaban use up to 15 ml/min in VTE. However, studies are still ongoing, and efforts to detect drug–drug interactions must be maintained given the risk of drugs accumulation.
2.2.2 Liver Diseases
Patients with liver disease have an increased thrombotic risk and bleeding risk. Anti-Xa DOACs are primarily eliminated via the CYP 3A4 metabolic pathways. Among them, apixaban has the greatest hepatic elimination (75%), while rivaroxaban and edoxaban are eliminated at 65% and 50% by the liver, respectively [20]. The European Medicines Agency does not recommend the use of apixaban in patients with liver disease associated with coagulopathy and a clinically relevant bleeding risk, aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 2 upper limit of normal (ULN), or liver disease expected to affect survival. In the general population, restrictions on their use in patients with cirrhosis are based on the Child–Pugh score [11, 20]. In case of cancer with cachexia, hypoalbuminemia Child–Pugh score could be overrated and may not provide a reliable evaluation of liver function.
All anti-Xa DOACs are contraindicated in the case of severe liver disease, but their use remains possible in the case of moderate liver disease without dose adjustment. In the event of a contraindication, the treatment option is LMWHs, as they are not affected by the liver metabolism.
2.2.3 Low Body Weight, Hypoalbuminemia and Malnutrition
Hypoalbuminemia, malnutrition and low body weight are frequently associated in patients with cancer. A proportion of 80% and 55% of patients with cancer have albumin plasma levels below 35 g/L and 20 g/L, respectively [21]. Anti-Xa DOACs are strongly bound to albumin. Hence, malnutrition and hypoalbuminemia are bleeding risk factors, not fully evaluated in specific studies in patients with CAT. Pharmacokinetic studies show a modification of the area under the curve (AUC) and Cmax. In patients weighing less than 60 kg, renal function assessment is important because conventional tests often overestimate renal function due to poor evaluation of muscle mass. Studies including atrial fibrillation patients or VTE reported fewer bleeding events in low weight patients (< 50 kg) with anti-Xa DOACs than with vitamin K antagonists (VKA) [11, 22].
2.2.4 Obesity
Various studies and one meta-analysis report comparable efficacy and safety of anti-Xa DOACs and low molecular weight heparin (LMWH) followed by VKA in patients with obesity without cancer [23]. Available data seem to show good safety and efficacy of anti-Xa DOACs for patients between 50 kg and 130 kg or for body mass index (BMI) up to 40–50 [22,23,24]. The use of doses adapted to body weight do not require monitoring of anti-Xa activity. LMWHs can be used for extreme weights up to 160 kg [11].
2.2.5 Thrombocytopaenia
Thrombocytopaenia can result from bone marrow infiltration or from anti-cancer medications and represents an important limitation for the use of anti-thrombotic treatments [25]. Post-chemotherapy thrombocytopaenia does not decrease the risk of VTE recurrence while it increases the risk of bleeding. Chemotherapy-induced thrombocytopaenia is a frequent complication of anti-neoplastic treatment. Severe thrombocytopaenia (< 10,000/µl) leads to an increased risk of bleeding [26]. Indeed, bleeding rates in this population range from 7 to 33% [27].
The risk of bleeding depends on the severity of thrombocytopaenia and its duration. According to an expert consensus, if the platelet count is > 50 × 109/L, there is no need to change the anti-coagulant therapy because the bleeding risk remains acceptable [28]. Clinical studies are warranted to precisely document the relationship between the risk of bleeding and thrombocytopenia.
If the platelet count is < 50 × 109/L, it may be necessary to transfuse platelets to maintain a full-dose anti-coagulant therapy with LMWH, if within 1 month of VTE diagnosis. After 1 month of anti-coagulant therapy, LMWH dose can be reduced without the need for platelet transfusion, because the risk of VTE recurrence is reduced [29]. There is no guidance to reduce anti-Xa DOAC doses in case of thrombocytopaenia, and a switch to LMWH is therefore recommended. Additionally, in all randomised clinical trials with DOACs in CAT, the cut-off for platelets rates at inclusion was 50 × 109/L.
2.2.6 Oral Drugs Malabsorption
Iterative nausea and vomiting induced by chemotherapy obviously alters the assimilation of drugs if they are rejected [30].
In the event of digestive surgical resection, the type of surgery influences the absorption of anti-Xa DOACs.
The mechanism of anti-Xa DOACs absorption varies from one drug to another. Rivaroxaban is absorbed primarily in the stomach and poorly in small intestine and colon; apixaban is absorbed primarily in the proximal small intestine with limited absorption in stomach and colon; and edoxaban is predominately absorbed in the proximal small intestine [31]. Gastrectomy reduces rivaroxaban plasma peak under therapeutic concentration, while apixaban concentration was shown to reach expected plasma concentration. Colectomy has no impact on anti-Xa DOACs concentration [24, 31, 32].
2.2.7 Elderly
Elderly patients frequently combine frailties: malnutrition with hypoalbuminemia, low muscle mass with risk of fall, renal insufficiency and co-medications, some of which may affect haemostasis. Elderly patients with cancer are a particularly frail population at risk for iatrogenic complications [33], especially as they are often poly-medicated [34].
Lesser-known but important drug–drug interactions with non-anti-neoplastic drugs
The use of anti-platelet agents is common in the population treated with concomitant anti-coagulants for atrial fibrillation leading to a higher rate of bleeding. In EINSTEIN [35, 36] and AMPLIFY [37] trials with rivaroxaban and apixaban, respectively, only low doses of aspirin below 165 mg daily were allowed and yet were associated with increased bleeding rates [hazard ratio (HR) 1.81].
Non-steroidal anti-inflammatory (NSAIDs) were also associated with a two-fold increase in bleeding risk, mainly related to gastric bleeding risk [38]. The concomitant use of anti-coagulants and selective serotonin reuptake inhibitors (SSRI) may be associated with a bleeding risk resulting from an interaction with platelets and serotonin [39]. This combination must be carefully considered as patients with cancer are frequently treated for depressive syndrome.
These accumulations of risk factors and frailties are additive to lesser-known DDIs. The risk of bleeding is amplified with the combination of both pharmacokinetic and pharmacodynamic interactions. This is the case with several anti-neoplastic agents that are associated with bleeding events, such as gastric petechiae, gastrointestinal and cerebral haemorrhage, which may occur rarely or very frequently depending on the drug. For example, in patients with chronic lymphoid leukaemia, the concomitant use of an anti-coagulant or a platelet inhibitor with a Bruton kinase inhibitor is associated with an increased major bleeding risk [40]. However, the concomitant use of an anti-cancer drug not metabolised by CYP3A4/5 or P-gp isoenzymes does not require any special precaution (e.g. fludarabine).
3 Drug–Drug Interactions in the Management of Patients with Cancer-Associated Thrombosis
The concomitant use of several drugs may potentially alter DOACs exposure thus increasing or decreasing their bioavailability and/or clearance. DDIs may therefore affect the efficacy and safety of DOAC therapy [41]. Anti-Xa DOACs are substrates of membrane P-glycoprotein (P-gp) which acts as an efflux pump by limiting the passage of drugs through the body’s main barriers, and therefore limiting their absorption. They do not significantly modify the metabolism of CYP450 3A4/5 or P-gp substrates, such as many anti-cancer drugs. This makes their use acceptable in patients with cancer. However, they may undergo variations to their own metabolism due to the concomitant use of inhibiting or inducing drugs. Their broad therapeutic index limits the impact of these pharmacokinetic interactions on their bioavailability, particularly in the case of moderate effect on metabolic pathways. Even though most of the known interactions are documented on pharmacological data, there is a lack of clinical data. However, in clinical practice, consideration should be given to the concomitant administration of moderate or potent inhibitors and/or inducers of CYP450 3A4/5 and P-gp as they may, depending on the clinical situation, significantly modify anti-Xa DOACs plasma concentrations [42]. Minor interactions are not discussed in this review as they have limited significant clinical impact.
3.1 Pharmacokinetic Interactions
The concomitant use of a DOAC and an anti-cancer drug that strongly inhibits or induces CYP3A4/5 or Pg-P metabolic pathways is not recommended, even though anti-Xa DOACs therapeutic index is broad. In this context the increase or the decrease in anti-Xa DOACs plasma levels may still result in increased bleeding or thrombotic risk, respectively. Examples of anti-cancer drugs effects on metabolic pathways are summarised in Table 2.
The initiation of an anti-cancer drug that moderately inhibits or induces CYP-450 3A4/5 or P-gp in a patient treated with DOAC warrants a thorough analysis of the bleeding or thrombotic risk of multifactorial origin such as:
-
Individual risk factors (age, renal function, nutritional status).
-
Risk factors related to the cancer disease: increased risk of bleeding in gastrointestinal, gynaecological and urothelial cancers, potentiated thrombotic risk in multiple myeloma, lung and pancreatic cancers.
-
Drug risk factors, in particular the concomitant use of drugs that inhibit or induce CYP3A4/5 or P-gp: vigilance is required for strong inhibitors of CYP3A4/5 (azole antifungals, mostly macrolides, etc.) or of P-gp (antiarrhythmics, such as amiodarone, etc.) if they must be maintained (Table 1). The concomitant use of non-anti-neoplastic drugs that strongly inhibit both CYP 3A4/5 and P-gp (i.e. telithromycin, ritonavir, itraconazole, etc.) may modify anti-Xa DOACs metabolism, thus increasing the bleeding risk and making the patient management particularly complex.
-
Potent inducers of both CYP3A4/5 and P-gp, such as anti-epileptics (carbamazepine, phenytoin, etc.) or anti-tuberculosis medications (rifampicin, etc.), can be considered with caution as they may be associated with an increase of the thrombotic risk.
-
Drug half-lives and dosing regimen: based on pharmacological criteria, the risk of drug–drug interactions may be limited during short-term applications of short half-life anti-cancer drugs, even though published data are lacking.
In all cases, increased vigilance is required in poly-medicated patients. It is crucial to keep in mind that strong CYP 3A4/5 inhibitors may increase the AUC of substrates five-fold or more. Strong inducers may decrease the AUC of substrates by 80% or more. In poly-medicated patients with cancer receiving anti-cancer drugs and anti-Xa DOACs, caution is particularly required in case of the concomitant use of strong CYP-450 3A4/5 and Pg-P inhibitors. Some of these treatments are frequently prescribed as macrolides (clarithromycin) or azole antifungal agents (itraconazole) [43].
If a decision to co-administer such drugs is made due to clinical reasons, close clinical monitoring is essential, potentially associated to a dose reduction, given the heterogeneity of available databases. Moreover, considering individualized doses according to anti-Xa DOACs plasma levels might be a good option but difficult to implement in the clinical practice. In addition, an exhaustive drug assessment should be performed to detect the use of self-medication, over-the-counter drugs or herbal products with potential inhibiting (milk thistle, grapefruit juice) or inducing (Saint John’s wort) properties, to avoid other causes of drug–drug interactions. Attention should be paid at the use of herbal products at pharmacological doses higher than the usual diet. Doses of curcuma higher than usual cooking doses may increase ibrutinib plasma levels and the bleeding risk of patients with chronic lymphocytic leukaemia, while gingerol derived from ginger may have similar effects when combined with dabrafenib/trametinib in patients with melanoma [44].
3.2 Pharmacodynamic Interactions
The initiation of an anti-cancer drug in a patient receiving an anti-coagulant requires an assessment for potential pharmacodynamic interactions, possibly resulting in either an increase or a reduction of the anti-coagulant effect. However, we must keep in mind that pharmacodynamic interactions are equally important for anti-Xa DOACs and low molecular weight heparins (LMWH).
Several anti-cancer drugs are known to have an additive effect to DOAC’s thus increasing the risk of bleeding. They include injectable drugs such as the anti-angiogenic bevacizumab used in the treatment of numerous solid tumours [45] or oral drugs, such as the anti-vascular endothelial growth factor (VEGF) regorafenib in patients with colorectal cancer [46], BCR-Abl inhibitors which are also inhibitors of platelet-derived growth factor such as imatinib in patients with chronic myeloid leukaemia [47], or Bruton tyrosine kinase inhibitors such as ibrutinib in patients with chronic lymphocytic leukaemia [40]. There is a lack of clinical data. However, the occurrence of bleeding was reported in patients treated with anti-VEGF and anti-Xa DOACs [HR of 4.15 (95% CI 0.38–45.0; p = 0,24)] compared with a group of patients treated with anti-Xa DOACs only [48]. Grade 3–4 bleedings were reported in patients concomitantly treated with ibrutinib and anti-Xa DOACs [49]. These findings were according to the multicentre international study conducted by the Scientific and Standardization Committee of the ISTH based on the TacDOAC registry assessing bleeding and thrombotic outcomes in patients receiving anti-Xa DOACs concomitantly with targeted anti-cancer therapies [50]. Some of them can cause adverse events such as petechiae, as well as gastrointestinal or cerebral haemorrhage, with a varied frequency and very diverse clinical consequences (grades 1–4). Their concomitant administration with a DOAC could potentiate the risk of bleeding by addition of effect, which justifies reinforced clinical and biological monitoring of the patient, and appropriate management in case of other situations with associated bleeding risk such as surgery, trauma and ongoing healing. A history of peptic ulcer should be sought.
Other anti-cancer drugs are associated with a thrombotic risk. This is the case of immune modulators or imids for the treatment of multiple myeloma [51] or hormone therapy such as tamoxifen approved for the treatment of breast cancer as a selective inhibitor of oestrogen receptors [52]. Despite the pharmacological inhibition of anti-Xa DOACs by tamoxifen, there is no evidence of an increased thrombotic recurrence risk with this combination [53].
In addition, several studies have shown that 20–70% of patients with cancer use self-medication and complementary alternative therapies, including phytotherapy [53,54,55]. The concomitant administration of an oral anti-cancer drug that inhibits CYP3A4/5 or P-gp and an anti-Xa DOAC requires the investigation of self-medication, such as aspirin or nonsteroidal anti-inflammatory drugs, and the intake of castor oil, fish liver oil and vitamin E which may increase the risk of bleeding.
4 Therapeutic Decision Algorithm
Bleeding risk represents the major concern when using anti-coagulants in patients with cancer, and the therapeutic decision process may be particularly complex. The potential of a DDI with anti-Xa DOACs should be carefully considered. LMWH are the preferred choice in the case of strong CYP 3A4/5 or P-gp metabolic interaction. In the case of moderate metabolic interaction, patient-related risks factors must be identified before considering the use of anti-Xa DOACs, particularly in frail patients. A simplified therapeutic decision algorithm for the management of the anti-coagulant treatment in patients with CAT is proposed in Fig. 1.
5 Conclusion
Co-morbidities and poly-medication are important determinants of frailty in patients with cancer. LMWHs and anti-Xa DOACs are recommended for the management of patients with CAT. However, given the risk of DDIs, the use of anti-Xa DOACs is particularly complex in this population at high risk for venous thromboembolism and bleeding. Therapeutic drug monitoring with measurement of plasma levels for all factor Xa inhibitors and/or anti-cancer drugs or LMWH activity is not widely available and not recommended in routine, but it could be helpful to rule out or confirm a clinically relevant DDI in case of major bleeding or thromboembolic recurrence. Appropriate management of these patients requires a multi-disciplinary approach including oncologists, vascular pathologies specialists, pharmacologists and pharmacists.
References
Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019. J Hematol Oncol. 2021;14(1):197.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23.
Verso M, Agnelli G, Munoz A, Connors JM, Sanchez O, Huisman M, Brenner B, Gussoni G, Cohen AT, Becattini C. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer. 2022;165:136–45.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4.
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Munoz A, Brenner B, Prata PH, Brilhante D, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–47.
Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Suryanarayan D, Tagalakis V, Wu C, et al. Treatment algorithm in cancer-associated thrombosis: updated canadian expert consensus. Curr Oncol. 2021;28(6):5434–51.
Nieto JA, Solano R, Ruiz-Ribo MD, Ruiz-Gimenez N, Prandoni P, Kearon C, Monreal M, Riete I. fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2010;8(6):1216–22.
Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Gimenez N, Fernandez-Capitan C, Valero B, Tiberio G, Bura-Riviere A, Monreal M, Investigators R. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb Res. 2013;132(2):175–9.
Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.
Mahe I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M, Perez Ductor C, Nieto S, Grandone E, Monreal M, et al. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med. 2017;130(3):337–47.
D. Morales Castro, L. Dresser, J. Granton, E. Fan. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62(2): 209–20.
Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol. 2013;2:21.
Bertoletti L, Ollier E, Duvillard C, Delavenne X, Beyens MN, De Magalhaes E, Bellet F, Basset T, Mismetti P, Laporte S. Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res. 2017;118:33–42.
Ciorcan M, Chisavu L, Mihaescu A, Gadalean F, Bob FR, Negru S, Schiller OM, Grosu ID, Marc L, Chisavu F, et al. Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. PLoS ONE. 2022;17(6): e0265930.
Grandone E, Aucella F, Barcellona D, Brunori G, Forneris G, Gresele P, Marietta M, Poli D, Testa S, Tripodi A, et al. Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. Blood Transfus. 2020;18(6):478–85.
Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1–12.
Jakowenko N, Nguyen S, Ruegger M, Dinh A, Salazar E, Donahue KR. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res. 2020;196:276–82.
Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 2018;71(19):2162–75.
Bossi P, Delrio P, Mascheroni A, Zanetti M. The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients. 2021;13(6):1980.
Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, Lopes RD, Garcia D, Crowther MA. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017;15(7):1322–33.
Mai V, Marceau-Ferron E, Bertoletti L, Lacasse Y, Bonnet S, Lega JC, Provencher S. Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: a systematic review with meta-analysis. Pharmacol Res. 2021;163: 105317.
Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874–82.
Falanga A, Leader A, Ambaglio C, Bagoly Z, Castaman G, Elalamy I, Lecumberri R, Niessner A, Pabinger I, Szmit S, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere. 2022;6(8): e750.
Mones JV, Soff G. Management of thrombocytopenia in cancer patients. Cancer Treat Res. 2019;179:139–50.
SamuelsonBannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(6):1246–9.
Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, et al. Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus. 2019;17(3):171–80.
Leader A, Ten Cate H, Spectre G, Beckers EAM, Falanga A. Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps. Crit Rev Oncol Hematol. 2018;132:76–88.
Riess H, Ay C, Bauersachs R, Becattini C, Beyer-Westendorf J, Cajfinger F, Chau I, Cohen AT, Khorana AA, Maraveyas A, et al. Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822–39.
Hakeam HA, Alkhani M, Alyahya Z, Alawaji Z, Ofori S. Direct acting oral anticoagulants following gastrointestinal tract surgery. J Cardiovasc Pharmacol. 2021;78(6):867–74.
Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). J Thromb Thrombolysis. 2017;43(3):343–51.
Mohile SG, Xian Y, Dale W, Fisher SG, Rodin M, Morrow GR, Neugut A, Hall W. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101(17):1206–15.
Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, et al. Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy. Oncologist. 2020;25(3):e502–11.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.
Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
Hreinsson JP, Kalaitzakis E, Gudmundsson S, Bjornsson ES. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol. 2013;48(4):439–47.
Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32.
EMA, Ibrutinib summary of procduct characteristics, https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_fr.pdf.
Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug–drug interactions with direct oral anticoagulants. Clin Pharmacokinet. 2020;59(8):967–80.
Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636–43.
FDA, Drug development and drug interactions|table of substrates, inhibitors and inducers. (2022). https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.
Pochet S, Lechon AS, Lescrainier C, De Vriese C, Mathieu V, Hamdani J, Souard F. Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database. Sci Rep. 2022;12(1):14178.
EMA, Bevacizumab summary of product characteristics. (2018). https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_fr.pdf.
EMA, Regorafenib summary of product characteristics. (2018). https://ec.europa.eu/health/documents/community-register/2018/20180522140864/anx_140864_fr.pdf.
EMA, Imatinib summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_fr.pdf.
Patel SH, George TL, Wang TF, Vogt SM, Folefac E, Xu M, Yang Y, Parikh AB, Verschraegen CF, Clinton SK, et al. Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. Cancer. 2021;127(6):938–45.
Raz MA, Arnason J, Bairey O, Shvidel L, Aviv A, Ben Baruch S, Perry C, Sarid N, Kirgner I, Dvid V, et al. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. Br J Haematol. 2020;189(2):e31–3.
Wang TF, Baumann Kreuziger L, Leader A, Spectre G, Lim MY, Gahagan A, Gangaraju R, Sanfilippo KM, Mallick R, Zwicker JI, et al. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2021;19(8):2068–81.
Debbie Jiang MD, Alfred Ian Lee MD. Thrombotic risk from chemotherapy and other cancer therapies. Cancer Treat Res. 2019;179:87–101.
Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D’Aiuto G, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111(5):650–6.
Damery S, Gratus C, Grieve R, Warmington S, Jones J, Routledge P, Greenfield S, Dowswell G, Sherriff J, Wilson S. The use of herbal medicines by people with cancer: a cross-sectional survey. Br J Cancer. 2011;104(6):927–33.
Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.
Theuser AK, Hack CC, Fasching PA, Antoniadis S, Grasruck K, Wasner S, Knoll S, Sievers H, Beckmann MW, Thiel FC. Patterns and trends of herbal medicine use among patients with gynecologic cancer. Geburtshilfe Frauenheilkd. 2021;81(6):699–707.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No external funding was used in the preparation of this manuscript.
Conflict of interest
Dr Claire Grange, Pr Catherine Rioufol, Pr Pierre-Jean Souquet and Dr Souad Assaad declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
Author contributions
Dr CG: conceptualisation, resources, writing, review and editing. Pr CR: conceptualisation, resources, writing and review. Pr P-JS: conceptualisation, resources, writing and review. Dr SA: conceptualisation, resources, writing and review.
Data availability
Not applicable.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Code availability
Not applicable.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Grange, C., Rioufol, C., Souquet, PJ. et al. Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions. Clin Pharmacokinet 62, 1523–1531 (2023). https://doi.org/10.1007/s40262-023-01298-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-023-01298-4